Priority STD Testing
Priority STD Testing is a St. Louis-based direct-to-consumer STD testing service that sells FDA-approved lab tests online and by phone, processing samples through Quest Diagnostics' 4,000+ collection facilities and delivering results via a secure patient portal within 24-48 hours.
- Company typePrivate
- Founded2001
- HeadquartersSt Louis, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Priority STD Testing does
Priority STD Testing is a privately held direct-to-consumer STD testing service founded in 2001 and headquartered in St. Louis, Missouri, operating with a team of 1-10 employees. The company enables individuals to purchase FDA-approved laboratory tests online or via phone 24/7, then visit one of more than 4,000 affiliated Quest Diagnostics collection facilities nationwide for sample collection, with results delivered through a secure HIPAA-compliant patient portal typically within 24-48 hours. The company's stated cumulative volume is over 100,000 individuals tested since inception.
The product portfolio spans individual tests priced from $69 to $159 and bundled panels, anchored by a $129 Twin STD Panel (Chlamydia and Gonorrhea) and a $249 10-Panel Test covering HIV (1 Ab, 1 Ag, 2 Ab), Hepatitis B and C, Syphilis, and Herpes 1/2. Specialty offerings include an HIV RNA Early Detection test capable of identifying the virus within 10 days of exposure, Herpes Early Detection with automatic confirmatory Inhibition testing for HSV-2 positives, and a Mycoplasma Genitalium test. Treatment services are provided through PWNHealth-affiliated physicians who conduct phone or video consultations and can prescribe medication for positive Chlamydia, Gonorrhea, or Trichomoniasis results, with a $65 consultation fee.
The business operates on a unit-pricing, pay-as-you-go model with no subscription component. Revenue is generated entirely from upfront test purchases plus optional physician consultation fees; there are no disclosed enterprise contracts, insurance billing arrangements, or recurring revenue streams. Marketing is primarily organic: SEO-optimized educational blog content, organic search, phone-based care counselors, Trustpilot review collection, and earned media coverage in Healthline, Vice, Huffington Post, and Men's Health. All laboratory processing is conducted in CLIA-certified labs via the Quest Diagnostics partnership, and the company is verified as a CDC NPIN provider.
Priority STD Testing firmographics
Firmographics- Name
- Priority STD Testing
- Legal name
- Priority STD Testing
- Website
- https://prioritystdtesting.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Priority STD Testing is a St. Louis-based direct-to-consumer STD testing service that sells FDA-approved lab tests online and by phone, processing samples through Quest Diagnostics' 4,000+ collection facilities and delivering results via a secure patient portal within 24-48 hours.
- Ownership category
- akta.pro rank
Priority STD Testing industry classification
Industry- Product category
- Direct-to-Consumer STD Testing Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Infectious Disease & STI Testing-to-Treatment with eRx + Pharmacy Fulfillment (HLALAIAL)
- akta.pro secondary industries
- Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)
Keywords
Where Priority STD Testing is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Priority STD Testing business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure
Revenue model
- Direct Test Sales: One-time purchase of STD testing panels and individual tests. Customers order online or by phone, pay upfront, then visit Quest Diagnostics collection facilities for sample collection. Additional $65 physician consultation fee for treatment consultations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Twin STD Panel - Chlamydia and Gonorrhea |
| Unit Pricing | Pay-as-you-go | 10-Panel STD Test - Comprehensive |
| Unit Pricing | Pay-as-you-go | Individual STD Tests |
| Unit Pricing | Pay-as-you-go | New York State Individual Tests |
| Unit Pricing | Pay-as-you-go | Physician Treatment Consultation |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Priority STD Testing product offering
Product offeringCore offering
Priority STD Testing is a direct-to-consumer STD testing service that lets individuals privately order lab tests online or by phone, visit any of 4,000+ Quest Diagnostics collection facilities nationwide without an appointment for sample collection, and receive confidential results through a secure online portal in 24-48 hours. The company also offers integrated physician consultations and treatment via PWNHealth for positive chlamydia, gonorrhea, or trichomoniasis results, with prescriptions called into local pharmacies.
Product overview
Priority STD Testing operates as a direct-to-consumer STD testing service offering a portfolio of individual tests and bundled panels. The core product lineup includes the Twin STD Panel (Chlamydia and Gonorrhea) and the 10-Panel STD Test as the most comprehensive option covering Hepatitis B, Hepatitis C, Syphilis, Herpes 1/2, and HIV 1/2. Individual standalone tests are available for each condition: Chlamydia ($99), Gonorrhea ($99), Hepatitis B ($69), Hepatitis C ($69), Herpes I/II ($109), HIV 1/2 ($89), Syphilis ($79), Trichomoniasis ($139), and Mycoplasma Genitalium ($159). Advanced early detection tests are offered for HIV RNA (detecting virus as early as 10 days post-exposure) and Herpes. The company also provides complementary physician consultation and treatment services through its PWNHealth partnership, enabling phone/video consults and prescriptions for positive results of curable STDs (Chlamydia, Gonorrhea, Trichomoniasis). Testing is conducted at over 4,000 private collection facilities nationwide with results typically available within 24-72 hours.
Differentiator
Problem solved
Functional benefit
Products and services
- Twin STD Panel (Chlamydia and Gonorrhea) Dual-test panel that screens for Chlamydia and Gonorrhea infections, priced at $129, for consumers wanting focused bacterial STD screening.
- 10-Panel STD Test Comprehensive 10-panel test covering Hepatitis B, Hepatitis C, Syphilis, Herpes 1, Herpes 2, HIV 1 Ab, HIV 1 Ag, HIV 2 Ab (plus Chlamydia and Gonorrhea per typical 10-panel composition), priced at $249 as the most popular option.
- Individual Chlamydia Test Standalone urine/blood test for Chlamydia infection, priced at $99, for patients seeking single-disease screening.
- Individual Gonorrhea Test Standalone test for Gonorrhea infection, priced at $99, allowing targeted screening for this bacterial STD.
- Individual Hepatitis B Test Standalone blood test for Hepatitis B virus, priced at $69, screening for liver infection transmittable through sexual contact and blood.
- Individual Hepatitis C Test Standalone test for Hepatitis C virus, priced at $69, detecting blood-borne liver infection that can be transmitted sexually.
- Herpes I/II Test Blood test detecting both Herpes Simplex Virus Type 1 (oral herpes) and Type 2 (genital herpes) antibodies, priced at $109.
- HIV 1/2 Test Standard 4th generation HIV test detecting both HIV-1 and HIV-2 antibodies, priced at $89.
- Individual Syphilis Test Blood test for Syphilis infection, priced at $79, screening for antibodies to Treponema pallidum bacterium.
- Individual Trichomoniasis Test Urine test for Trichomoniasis infection, priced at $139, screening for the Trichomonas vaginalis parasite.
- Mycoplasma Genitalium Test Test for Mycoplasma genitalium infection, priced at $159, offered as part of the company's expanded STD testing menu.
- HIV RNA Early Detection Test Advanced HIV test detecting viral RNA rather than antibodies, enabling detection as early as 10 days after exposure; results typically process in about 5 business days due to specialty lab requirements.
- Herpes Early Detection Test Early detection testing for Herpes simplex virus, with automatic confirmatory inhibition testing for HSV-2 positive results at no additional charge.
- Physician Consultation Service Phone or video consultation with a PWNHealth physician for patients testing positive for Chlamydia, Gonorrhea, or Trichomoniasis, at a $65 consultation fee, enabling prescription medication without an office visit.
- Treatment Services Prescription treatment for patients testing positive for Chlamydia, Gonorrhea, or Trichomoniasis, with medication called into the patient's pharmacy of choice and typically available same day, delivered via PWNHealth physicians.
Quantifiable outcome
- Results available in 24-48 hours
- +2 more outcomes
Companies that use Priority STD Testing
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Priority STD Testing technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature3 records
Priority STD Testing partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Quest DiagnosticscoreQuest Diagnostics is the primary laboratory partner responsible for collecting and processing all samples. They operate the 4,000+ collection facilities where customers provide urine and blood samples. Quest Diagnostics is in compliance with federal, state, and local health reporting requirements.
- PWNHealthcorePWNHealth provides administrative services including physician review of test orders, results delivery through secure patient portal, and phone/video consultations for treatment of positive results. PWN physicians can prescribe medication for chlamydia, gonorrhea, and trichomoniasis. Located at 123 W 18th St, New York, NY 10011.
- TrustpilotminorTrustpilot is used to collect and display customer reviews of the testing experience. Automated review requests are sent via email after testing is complete. No medically related information is disclosed in the review system.
Scale indicators4 records
Recent moves6 records
Expansion highlights3 records
Priority STD Testing competitors and assessment
Company assessmentDirect peers
- myLAB Box: At-home STI testing company offering mail-in sample collection kits covering chlamydia, gonorrhea, HIV, HPV, and other infections. Competes for the same privacy-conscious, insurance-avoiding consumer segment but differentiates through home collection rather than walk-in labs.
- STDcheck.com: Direct-to-consumer STD testing service using the same Quest Diagnostics lab network and offering nearly identical panels (Twin Panel, 10-Panel, individual tests). Operates an almost identical online-order-plus-walk-in-lab model with confidential results, making it the closest head-to-head competitor.
- Everlywell: D2C at-home testing company offering STI panels among a broad diagnostics menu. Owned by Quest Diagnostics (Priority STD Testing's lab partner), creating both a competitive threat and a structural risk that Quest could prioritize Everlywell's funnel.
- LetsGetChecked: Direct-to-consumer at-home health testing platform offering STI panels alongside broader wellness, hormone, and chronic-condition tests. Backed by significant venture funding, it competes for the same consumer willingness to pay out-of-pocket for private testing.
- STDtesting.com: DTC STD testing provider offering individual and panel tests with online ordering and walk-in lab visits. Closely matches Priority STD Testing's value proposition of convenience, confidentiality, and fast turnaround via national lab partnerships.
Emerging players
- Roman (Ro): Telehealth company offering men's sexual health services including STI testing, ED treatment, and PrEP. Targets a partially overlapping male consumer segment and offers integrated testing-to-treatment pathways that compete with Priority's positive-result consultation workflow.
- Nurx: Telehealth platform offering at-home STI testing kits alongside prescription contraception, HPV screening, and PrEP. Competes for the same privacy-conscious consumer and overlaps in the testing-to-treatment workflow that Priority STD Testing offers via PWNHealth.
Broad incumbents
- Quest Diagnostics: One of the two largest clinical laboratory networks in the U.S. and Priority STD Testing's exclusive lab processing partner. Operates the 4,000+ collection sites used by Priority and increasingly competes via its own D2C channels (QuestDirect, Everlywell).
Others
- Labcorp: Other dominant U.S. clinical laboratory network with national collection footprint and a growing direct-to-consumer testing offering (Labcorp OnDemand). Comparable as both a potential lab partner alternative and as an incumbent competing for the same testing demand.
- PWNHealth: Physician network and clinical services provider supplying Priority STD Testing's telehealth consultation and prescription infrastructure. While a strategic partner rather than a customer-facing competitor, PWNHealth is increasingly enabling direct D2C testing services for other brands, posing both ecosystem dependence and competitive risk.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Priority STD Testing social profiles
Digital presencePriority STD Testing compliance and trust
Trust signalCompliance5 records
Priority STD Testing financial estimates
Financial estimateRevenue estimate
Valuation estimate
Priority STD Testing leadership team
Management profileNumber of profiles
Profiles1 record
Priority STD Testing funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Priority STD Testing M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Priority STD Testing
What does Priority STD Testing do?
Priority STD Testing is a direct-to-consumer STD testing service that lets individuals privately order lab tests online or by phone, visit any of 4,000+ Quest Diagnostics collection facilities nationwide without an appointment for sample collection, and receive confidential results through a secure online portal in 24-48 hours. The company also offers integrated physician consultations and treatment via PWNHealth for positive chlamydia, gonorrhea, or trichomoniasis results, with prescriptions called into local pharmacies.
Is Priority STD Testing a public or private company?
Priority STD Testing is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Priority STD Testing founded?
Priority STD Testing was founded in 2001. It employs 1 to 10 people.
Where is Priority STD Testing based?
Priority STD Testing is headquartered in St Louis, United States, in the North America region.
How does Priority STD Testing make money?
One revenue line is on record: direct Test Sales.
Who are Priority STD Testing's main competitors?
Direct peers on record are myLAB Box, STDcheck.com, Everlywell, LetsGetChecked and STDtesting.com. Emerging players are Roman (Ro) and Nurx. Quest Diagnostics is listed as a broad incumbent. Others are Labcorp and PWNHealth.
Does Priority STD Testing have an API?
No public API is recorded for Priority STD Testing.
What industry is Priority STD Testing in?
Priority STD Testing's product category is Direct-to-Consumer STD Testing Services. Its primary akta.pro industry code is HLALAIAL, Infectious Disease & STI Testing-to-Treatment with eRx + Pharmacy Fulfillment, with a secondary code of HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis). Its NAICS code is 621511 and its SIC code is 8071.